Selinexor
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Selinexor: From Multiple Myeloma to Drug-Induced Osteoporosis
One-Sentence Summary
Selinexor is a selective inhibitor of nuclear export (SINE) approved internationally for multiple myeloma and diffuse large B-cell lymphoma. The TxGNN model predicts a possible association with Drug-Induced Osteoporosis, but this prediction is currently not supported by any clinical trials or published literature — it is a model-only inference.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (no licensed indications recorded; drug is not marketed in Taiwan) |
| Predicted New Indication | Drug-Induced Osteoporosis |
| TxGNN Prediction Score | 99.22% |
| Evidence Level | L5 |
| US Market Status | 未上市 (Not marketed in Taiwan) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known public pharmacology, selinexor is a selective inhibitor of nuclear export (SINE) that targets XPO1/CRM1, and is approved internationally for multiple myeloma and diffuse large B-cell lymphoma. By blocking XPO1-mediated nuclear export, selinexor forces retention of tumor suppressor proteins and disrupts NF-κB signaling in malignant cells.
The proposed link to drug-induced osteoporosis is purely theoretical: osteoclast differentiation (osteoclastogenesis) partly depends on NF-κB activation, so XPO1 inhibition could plausibly interfere with this pathway. However, this is an indirect mechanistic inference, not an established pharmacological relationship. Importantly, selinexor’s well-documented clinical side effects — anorexia, weight loss, and fatigue — could just as plausibly worsen bone loss through poor nutritional status, making the direction of any real-world effect on bone density uncertain.
No direct experimental or clinical evidence currently supports selinexor for treating or preventing drug-induced osteoporosis.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
Selinexor is not currently marketed in Taiwan (0 licenses on record). No NDA/license information is available.
Cytotoxicity (Antineoplastic Drugs Only)
Selinexor is classified as an antineoplastic agent (approved for multiple myeloma / DLBCL) and is included here for reference, though its original indication text was not available in this Evidence Pack.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (XPO1/CRM1 selective inhibitor — SINE compound) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Must follow cytotoxic/targeted anti-cancer drug handling regulations |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: This prediction rests solely on a theoretical mechanistic hypothesis (L5, model prediction only), with zero clinical trials or literature support, and the drug is not currently marketed in Taiwan.
To proceed, the following is needed:
- Confirmed drug MOA data from DrugBank (currently flagged as a data gap, DG002)
- TFDA label warnings/contraindications (currently flagged as a blocking data gap, DG001 — required before any S1 safety review)
- Preclinical or mechanistic studies directly examining XPO1 inhibition and bone metabolism/osteoclastogenesis
- Real-world or trial-derived bone density/fracture data from existing selinexor oncology trials, if available
- Reassessment of net effect on bone health given selinexor’s known anorexia/weight-loss adverse effect profile
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.